# Elanco Animal Health Incorporated (ELAN) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $24.50, market value $12.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Elanco Animal Health Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.4×**. Each dollar of revenue is priced at 2.4×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.1%** (5-yr avg 3.6%). Free cash flow equals 3.1% of the market value, in line with its five-year average of 3.6%.

## Profitability
- **Gross margin: 55.4%**. Elanco Animal Health Incorporated keeps 55.4% of revenue after the direct cost of what it sells.
- **Net margin: -4.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -3.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -1.5%**. Each dollar of assets produces -1.5% of profit.

## Growth
- **Revenue growth (1 yr): 6.2%** (3-yr 2.2%/yr, 5-yr 7.6%/yr). Revenue grew 6.2% over the last year, against 7.6% a year compounded over five years.
- **EPS growth (1 yr): -169.1%**. Earnings per share fell 169.1%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 0.4%/yr**. Free cash flow has compounded at 0.4% a year over three years.

## Financial health
- **Debt to equity: 0.57**. Debt is 0.57 times equity, moderate leverage.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Elanco Animal Health Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (14 analysts). 14 analysts cover Elanco Animal Health Incorporated; the consensus is strong_buy, with an average price target of $31.21 (+27% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 40.2%** (YTD 8.3%, 3-mo 3.7%). The shares are up 40.2% over twelve months including dividends.
- **From 52-week high: -12.4%** (34.5% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.33** (volatility 43%). Beta of 1.33 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ELAN · Page: https://foliofundamentals.com/stocks/elan

Not investment advice.